JP2022520428A5 - - Google Patents
Info
- Publication number
- JP2022520428A5 JP2022520428A5 JP2021547336A JP2021547336A JP2022520428A5 JP 2022520428 A5 JP2022520428 A5 JP 2022520428A5 JP 2021547336 A JP2021547336 A JP 2021547336A JP 2021547336 A JP2021547336 A JP 2021547336A JP 2022520428 A5 JP2022520428 A5 JP 2022520428A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- ribonucleic acid
- manipulated
- composition according
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023146414A JP7502537B2 (ja) | 2019-02-14 | 2023-09-08 | Ｒｕｖｃドメインを有する酵素 |
| JP2024091759A JP2024133476A (ja) | 2019-02-14 | 2024-06-05 | Ｒｕｖｃドメインを有する酵素 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805899P | 2019-02-14 | 2019-02-14 | |
| US201962805868P | 2019-02-14 | 2019-02-14 | |
| US201962805878P | 2019-02-14 | 2019-02-14 | |
| US62/805,868 | 2019-02-14 | ||
| US62/805,878 | 2019-02-14 | ||
| US62/805,899 | 2019-02-14 | ||
| US201962874414P | 2019-07-15 | 2019-07-15 | |
| US62/874,414 | 2019-07-15 | ||
| PCT/US2020/018432 WO2020168291A1 (en) | 2019-02-14 | 2020-02-14 | Enzymes with ruvc domains |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146414A Division JP7502537B2 (ja) | 2019-02-14 | 2023-09-08 | Ｒｕｖｃドメインを有する酵素 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022520428A JP2022520428A (ja) | 2022-03-30 |
| JP2022520428A5 true JP2022520428A5 (enExample) | 2023-02-21 |
Family
ID=72045639
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547336A Ceased JP2022520428A (ja) | 2019-02-14 | 2020-02-14 | Ｒｕｖｃドメインを有する酵素 |
| JP2023146414A Active JP7502537B2 (ja) | 2019-02-14 | 2023-09-08 | Ｒｕｖｃドメインを有する酵素 |
| JP2024091759A Pending JP2024133476A (ja) | 2019-02-14 | 2024-06-05 | Ｒｕｖｃドメインを有する酵素 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023146414A Active JP7502537B2 (ja) | 2019-02-14 | 2023-09-08 | Ｒｕｖｃドメインを有する酵素 |
| JP2024091759A Pending JP2024133476A (ja) | 2019-02-14 | 2024-06-05 | Ｒｕｖｃドメインを有する酵素 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240117330A1 (enExample) |
| EP (1) | EP3924482A4 (enExample) |
| JP (3) | JP2022520428A (enExample) |
| KR (2) | KR20240007322A (enExample) |
| CN (2) | CN116515797A (enExample) |
| AU (3) | AU2020223370B2 (enExample) |
| CA (2) | CA3241703C (enExample) |
| MX (2) | MX2021009886A (enExample) |
| WO (1) | WO2020168291A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021178933A2 (en) | 2020-03-06 | 2021-09-10 | Metagenomi Ip Technologies, Llc | Class ii, type v crispr systems |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| WO2021226363A1 (en) * | 2020-05-08 | 2021-11-11 | Metagenomi Ip Technologies, Llc | Enzymes with ruvc domains |
| CA3241703C (en) * | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| GB2594339B (en) * | 2020-02-14 | 2023-02-08 | Metagenomi Inc | Enzymes with RUVC domains |
| WO2021202568A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi Ip Technologies, Llc | Class ii, type ii crispr systems |
| EP4165177A4 (en) * | 2020-05-08 | 2024-08-28 | Metagenomi, Inc. | ENZYMES WITH RUVC DOMAINS |
| JP2023540797A (ja) | 2020-09-11 | 2023-09-26 | メタゲノミ，インコーポレイテッド | 塩基編集酵素 |
| GB2700205B (en) * | 2020-09-11 | 2026-04-15 | Metagenomi Therapeutics Inc | Base editing enzymes |
| WO2022087135A1 (en) * | 2020-10-21 | 2022-04-28 | Emendobio Inc. | Novel omni 56, 58, 65, 68, 71, 75, 78, and 84 crispr nucleases |
| WO2022098681A2 (en) * | 2020-11-03 | 2022-05-12 | Caspr Biotech Corporation | Novel class 2 crispr-cas rna-guided endonucleases |
| CA3205865A1 (en) * | 2021-01-22 | 2022-07-28 | Brian C. Thomas | Novel engineered and chimeric nucleases |
| WO2022159742A1 (en) * | 2021-01-22 | 2022-07-28 | Metagenomi, Inc | Novel engineered and chimeric nucleases |
| JP2024515936A (ja) * | 2021-03-19 | 2024-04-11 | メタゲノミ，インク． | Ｃａｓ酵素を用いたマルチプレックス編集 |
| KR20240004618A (ko) * | 2021-04-30 | 2024-01-11 | 메타지노미, 인크. | Ruvc 도메인을 갖는 효소 |
| AU2022335499A1 (en) | 2021-08-27 | 2024-02-22 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| WO2023081855A1 (en) | 2021-11-05 | 2023-05-11 | Metagenomi, Inc. | Base editing enzymes |
| AU2022396533A1 (en) | 2021-11-24 | 2024-05-02 | Metagenomi Therapeutics, Inc. | Endonuclease systems |
| WO2023122663A2 (en) * | 2021-12-23 | 2023-06-29 | Mammoth Biosciences, Inc. | Effector proteins and methods of use |
| WO2023194359A1 (en) * | 2022-04-04 | 2023-10-12 | Alia Therapeutics Srl | Compositions and methods for treatment of usher syndrome type 2a |
| KR20250037788A (ko) * | 2022-06-15 | 2025-03-18 | 빔 테라퓨틱스, 인크. | 보체 활성화를 감소시키기 위한 조성물 및 방법 |
| CA3267752A1 (en) * | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | ENQP TYPE II CAS PROTEINS AND THEIR APPLICATIONS |
| AU2024230342A1 (en) * | 2023-03-01 | 2025-10-16 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
| WO2025106934A1 (en) * | 2023-11-16 | 2025-05-22 | Metagenomi, Inc. | Enzymes with ruvc domains |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113355357B (zh) * | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| WO2016196655A1 (en) * | 2015-06-03 | 2016-12-08 | The Regents Of The University Of California | Cas9 variants and methods of use thereof |
| WO2016205759A1 (en) * | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
| EP3500967A1 (en) * | 2016-08-17 | 2019-06-26 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| WO2019165168A1 (en) * | 2018-02-23 | 2019-08-29 | Pioneer Hi-Bred International, Inc. | Novel cas9 orthologs |
| CA3241703C (en) * | 2019-02-14 | 2026-02-24 | Metagenomi Therapeutics, Inc. | Enzymes with ruvc domains |
-
2020
- 2020-02-14 CA CA3241703A patent/CA3241703C/en active Active
- 2020-02-14 KR KR1020247000311A patent/KR20240007322A/ko active Pending
- 2020-02-14 AU AU2020223370A patent/AU2020223370B2/en active Active
- 2020-02-14 CA CA3130135A patent/CA3130135C/en active Active
- 2020-02-14 EP EP20756259.6A patent/EP3924482A4/en active Pending
- 2020-02-14 CN CN202310441977.6A patent/CN116515797A/zh active Pending
- 2020-02-14 JP JP2021547336A patent/JP2022520428A/ja not_active Ceased
- 2020-02-14 WO PCT/US2020/018432 patent/WO2020168291A1/en not_active Ceased
- 2020-02-14 MX MX2021009886A patent/MX2021009886A/es unknown
- 2020-02-14 KR KR1020217028874A patent/KR102623312B1/ko active Active
- 2020-02-14 CN CN202080028787.6A patent/CN113728098A/zh active Pending
-
2021
- 2021-08-16 MX MX2023006575A patent/MX2023006575A/es unknown
-
2023
- 2023-06-15 US US18/335,481 patent/US20240117330A1/en active Pending
- 2023-07-17 AU AU2023206079A patent/AU2023206079A1/en not_active Abandoned
- 2023-09-08 JP JP2023146414A patent/JP7502537B2/ja active Active
-
2024
- 2024-06-05 JP JP2024091759A patent/JP2024133476A/ja active Pending
-
2025
- 2025-12-11 AU AU2025279720A patent/AU2025279720A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022520428A5 (enExample) | ||
| JP2023519953A5 (enExample) | ||
| JP2023517041A5 (enExample) | ||
| US20230123754A1 (en) | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | |
| JP2024535672A5 (enExample) | ||
| JP2022531347A5 (enExample) | ||
| CN111836894B (zh) | 用于使用CRISPR/Cpf1系统进行基因组编辑的组合物及其用途 | |
| JP2024541402A5 (enExample) | ||
| JP2023540797A5 (enExample) | ||
| Sampson et al. | Exploiting CRISPR/C as systems for biotechnology | |
| JP2025181841A5 (enExample) | ||
| JP2021530988A5 (enExample) | ||
| Gryaznov | Oligonucleotide N3′→ P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents | |
| JP2019524149A5 (enExample) | ||
| CN115697420A (zh) | 一种治疗赫勒氏综合征的方法和药物 | |
| CN106554969A (zh) | 基于抑菌杀菌的多靶点CRISPR/Cas9表达载体 | |
| JP2020512845A5 (enExample) | ||
| JP2024517607A5 (enExample) | ||
| JP2015534817A5 (enExample) | ||
| GB2612458A (en) | Enzymes with RuvC domains | |
| RU2015128098A (ru) | Конструирование систем, способы и оптимизированные направляющие композиции для манипуляции с последовательностями | |
| JP2016502858A5 (enExample) | ||
| WO2013141680A1 (en) | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX | |
| RU2022103641A (ru) | Искусственная модификация генома для регуляции экспрессии гена | |
| JP2020536506A5 (enExample) |